Vertex said Monday that a drug it secured as part of a
$4.9 billion acquisition
successfully reduced by half a key marker of a kidney disease known as IgA nephropathy.
The results, from a Phase 3 trial, match data from a study of Otsuka’s
recently approved Voyxact
and are numerically superior to data released last year by
Vera Therapeutics
.
All three companies have been racing to treat a disease that affects 330,000 people across the U.S. and Europe, according to Vertex’s estimates, putting many at risk of developing end-stage renal disease. Analysts have projected Vertex’s drug could eventually bring in $4 billion or more in annual sales.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/03/09/vertex-iga-nephropathy-study-results/)
